Haitian-born billionaire Herriot Tabuteau's Axsome begins Phase 3 ADHD trial in children
Axsome Therapeutics, led by Haitian-born billionaire Herriot Tabuteau, has dosed the first child in a Phase 3 trial of solriamfetol for ADHD.
Skip to content
Axsome Therapeutics, led by Haitian-born billionaire Herriot Tabuteau, has dosed the first child in a Phase 3 trial of solriamfetol for ADHD.
Shares of Axsome Therapeutics have doubled in nine months, pushing the net worth of Haiti-born founder Herriot Tabuteau to $2.2 billion.
Axsome Therapeutics CEO Herriot Tabuteau sold 49,670 shares worth $11.97 million on June 9 under a pre-approved trading plan as AXSM trades near record highs.